Figure 7From: Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trialSurvival analysis in relation to collective biomarker expression. Overall survival in patients treated with adjuvant 5-FU/FA versus 5-FU/FA/irinotecan in patients negative for AREG, EREG, Hif-1 α and positive for PTEN (A) and in patients negative for AREG, EREG and positive for PTEN (B).Back to article page